Lucas Boyd Kipp, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kipp’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A137774 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · University of Western Ontario Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,588
Medicare paid this office $16,588 for 72 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 48 | $7,677 | $116 |
| Long return visit (40+ min) | 33 | $6,000 | $143 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $455 | $23 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 19 | $300 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 11 | $165 | $15 |
Who their Medicare patients are
72 Original Medicare patients in 2024. Average age 62 · Under 65 49% · 85 and older 0% · Women 72% · Also on Medicaid 33% · Health risk score 1.49. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 47% · Depression 32% · Diabetes 18%.
The office billed $66,695, Medicare allowed $22,771 and paid $16,588; for 174 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 72 | 174 | 62 | 1.49 | $66,695 | $16,588 |
| 2023 | 79 | 148 | 62 | 1.22 | $56,634 | $15,120 |
| 2022 | 67 | 134 | 61 | 1.22 | $47,248 | $14,230 |
| 2021 | 67 | 134 | 61 | 1.21 | $42,439 | $13,842 |
| 2020 | 63 | 91 | 60 | 1.32 | $30,386 | $9,188 |
| 2019 | 47 | 70 | 62 | 1.45 | $11,363 | $7,534 |
| 2018 | 59 | 105 | 63 | 1.58 | $16,418 | $10,951 |
| 2017 | 60 | 97 | 65 | 1.46 | $26,482 | $10,538 |
| 2016 | 23 | 31 | 60 | 1.31 | $11,412 | $3,752 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 66 | $12,153 | $119 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $319 | $16 |
2022: 2 services
| Long return visit (40+ min) | 58 | $11,655 | $124 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $677 | $29 |
2021: 3 services
| Long return visit (40+ min) | 57 | $10,212 | $116 |
| New patient visit (60+ min) | 16 | $2,573 | $161 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $809 | $30 |
2020: 2 services
| Long return visit (40+ min) | 42 | $5,741 | $93 |
| New patient visit (60+ min) | 20 | $2,791 | $140 |
2019: 2 services
| Long return visit (40+ min) | 32 | $4,905 | $94 |
| New patient visit (60+ min) | 17 | $2,589 | $152 |
2018: 3 services
| Long return visit (40+ min) | 41 | $6,278 | $92 |
| New patient visit (60+ min) | 21 | $2,874 | $137 |
| Long return visit (40+ min) | 11 | $1,197 | $100 |
2017: 2 services
| Long return visit (40+ min) | 40 | $5,280 | $91 |
| New patient visit (60+ min) | 35 | $4,930 | $141 |
2016: 2 services
| New patient visit (60+ min) | 14 | $2,096 | $150 |
| Long return visit (40+ min) | 13 | $1,585 | $99 |
Medicaid work
$2,661 in 2023
Medicaid paid $2,661 for 51 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 51 | $2,661 |
| 2023 | 51 | 1 | 13 | $2,661 |
| 2022 | 13 | 1 | 13 | $950 |
See the largest Medicaid services in earlier years
2022
| Long return visit (40+ min) | 13 | $950 |
Drugs they prescribed that Part D paid
$204,768
Pharmacies billed $204,768 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 344) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
316 generic and 28 brand-name prescriptions · $204,768 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fingolimod | 23 | $46,512 | $2,022 |
| Nuedexta | 12 | $16,118 | $1,343 |
| Modafinil | 15 | $6,623 | $442 |
| Dimethyl | 28 | $4,714 | $168 |
| Sumatriptan | 26 | $1,118 | $43 |
See all 12 drugs
| Fingolimod | 23 | $46,512 | $2,022 |
| Nuedexta | 12 | $16,118 | $1,343 |
| Modafinil | 15 | $6,623 | $442 |
| Dimethyl | 28 | $4,714 | $168 |
| Sumatriptan | 26 | $1,118 | $43 |
| Baclofen | 35 | $901 | $26 |
| Pregabalin | 30 | $765 | $26 |
| Gabapentin | 59 | $687 | $12 |
| Duloxetine | 37 | $511 | $14 |
| Rizatriptan | 17 | $161 | $9 |
| Sertraline | 13 | $55 | $4 |
| Clonazepam | 11 | $50 | $5 |
Year by year
| 2024 | 344 | 37 | 0% (0) | 8% | $204,768 |
| 2023 | 315 | 33 | 0% (0) | 8% | $268,842 |
| 2022 | 192 | 31 | 0% (0) | 20% | $296,527 |
| 2021 | 258 | 27 | 0% (0) | 28% | $457,774 |
| 2020 | 209 | 23 | 0% (0) | 33% | $278,618 |
| 2019 | 174 | 18 | 0% (0) | 45% | $416,904 |
| 2018 | 187 | 23 | 0% (0) | 58% | $474,328 |
| 2017 | 137 | 22 | 0% (0) | 49% | $258,340 |
| 2016 | 21 | None | 0% (0) | 67% | $73,172 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Dimethyl | 40 | $50,906 | $1,273 |
| Ampyra | 11 | $41,910 | $3,810 |
| Fingolimod | 14 | $18,160 | $1,297 |
| Modafinil | 23 | $1,378 | $60 |
| Baclofen | 25 | $1,317 | $53 |
| Gabapentin | 68 | $979 | $14 |
| Pregabalin | 18 | $943 | $52 |
| Duloxetine | 24 | $940 | $39 |
| Sumatriptan | 18 | $686 | $38 |
| Rizatriptan | 17 | $307 | $18 |
| Clonazepam | 11 | $77 | $7 |
2022: 7 drugs
| Ampyra | 12 | $41,566 | $3,464 |
| Dimethyl | 25 | $10,382 | $415 |
| Pregabalin | 20 | $1,105 | $55 |
| Gabapentin | 28 | $459 | $16 |
| Baclofen | 14 | $331 | $24 |
| Rizatriptan | 11 | $208 | $19 |
| Sumatriptan | 11 | $64 | $6 |
2021: 11 drugs
| Copaxone | 19 | $106,449 | $5,603 |
| Tecfidera | 11 | $96,685 | $8,790 |
| Ampyra | 12 | $40,811 | $3,401 |
| Dimethyl | 20 | $25,863 | $1,293 |
| Myrbetriq | 11 | $8,381 | $762 |
| Pregabalin | 23 | $2,299 | $100 |
| Gabapentin | 37 | $824 | $22 |
| Oxybutynin Chloride Er | 17 | $427 | $25 |
| Rizatriptan | 12 | $227 | $19 |
| Clonazepam | 15 | $58 | $4 |
| Sertraline | 13 | $18 | $1 |
2020: 7 drugs
| Aubagio | 13 | $96,783 | $7,445 |
| Copaxone | 14 | $61,979 | $4,427 |
| Ampyra | 13 | $37,560 | $2,889 |
| Myrbetriq | 21 | $10,495 | $500 |
| Baclofen | 15 | $679 | $45 |
| Gabapentin | 38 | $517 | $14 |
| Tizanidine | 17 | $434 | $26 |
2019: 7 drugs
| Tecfidera | 19 | $147,730 | $7,775 |
| Aubagio | 17 | $114,391 | $6,729 |
| Ampyra | 13 | $36,353 | $2,796 |
| Myrbetriq | 15 | $6,784 | $452 |
| Dalfampridine Er | 17 | $4,337 | $255 |
| Tizanidine | 11 | $416 | $38 |
| Gabapentin | 30 | $302 | $10 |
2018: 8 drugs
| Aubagio | 22 | $141,592 | $6,436 |
| Tecfidera | 19 | $139,321 | $7,333 |
| Copaxone | 18 | $110,792 | $6,155 |
| Ampyra | 23 | $61,541 | $2,676 |
| Myrbetriq | 14 | $5,972 | $427 |
| Oxybutynin Chloride Er | 11 | $738 | $67 |
| Tizanidine | 15 | $553 | $37 |
| Gabapentin | 29 | $512 | $18 |
2017: 4 drugs
| Tecfidera | 13 | $103,188 | $7,938 |
| Ampyra | 16 | $36,034 | $2,252 |
| Baclofen | 13 | $317 | $24 |
| Gabapentin | 20 | $285 | $14 |
Money from drug and device companies
$210 in 2025
| 2025 | 1 | 2 | None | $210 |
| 2022 | 1 | 2 | None | $109 |
| 2021 | 2 | 2 | None | $34 |
| 2020 | 3 | 4 | None | $91 |
| 2019 | 3 | 5 | None | $278 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | Ocrevus | $210 | 2 payments
|
See all 2 published payments
| Genentech | Meals · 2025-09-25 | Ocrevus | $101 |
| Genentech | Meals · 2025-05-29 | Ocrevus | $109 |
See earlier years (2022, 2021, 2020, 2019)
2022: $109
| Biogen | Tysabri | $109 | 2 payments
|
2021: $34
| E.R. Squibb & Sons L.L.C. | Zeposia | $18 | 1 payment
|
| Celgene | Zeposia | $16 | 1 payment
|
2020: $91
| Biogen | Tysabri | $37 | 2 payments
|
| EMD Serono | Mavenclad | $35 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $19 | 1 payment
|
2019: $278
| Novartis Pharmaceuticals | Mayzent | $124 | 3 payments
|
| EMD Serono | Mavenclad | $88 | 1 payment
|
| Alexion Pharmaceuticals | None | $67 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2023 | Their institution | $129,891 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2024 | Their institution | $122,727 |
| Genentech, Inc. · Ocrelizumab Rms High Dose Study · 2024 | Their institution | $96,980 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2025 | Their institution | $92,991 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2022 | Their institution | $76,226 |
| Genentech, Inc. · Ocrelizumab Rms High Dose Study · 2025 | Their institution | $63,113 |
| Biogen, Inc. · A Study To Evaluate Efficacy, Safety, and Tolerability of Eid of Natalizumab (Bg00002) in Participants With Rrms Switching From Treatment With Natalizumab Sid in Relation To Continued Sid Treatment- Followed By Extension Study Comprising Sc and IV Natalizumab Administration · 2020 | Their institution | $59,547 |
| Biogen, Inc. · A Study To Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (Bg00002) in Participants With Relapsing-Remitting Multiple Sclerosis (Rrms) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (Sid) in Relation To Continued Sid Treatment · 2019 | Their institution | $55,243 |
| Biogen, Inc. · A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (Bg00002) in Subjects With Relapsing-Remitting Multiple Sclerosisswitching From Treatment With 4-Week Natalizumab Standard Interval Dosing (Sid) in Relation To Continued Sid Treatment · 2022 | Their institution | $39,433 |
| Biogen, Inc. · A Study To Evaluate Efficacy, Safety, and Tolerability of Eid of Natalizumab (Bg00002) in Participants With Rrms Switching From Treatment With Natalizumab Sid in Relation To Continued Sid Treatment- Followed By Extension Study Comprising Sc and IV Natalizumab Administration · 2021 | Their institution | $30,452 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2021 | Their institution | $20,262 |
| Genentech, Inc. · Evaluation of Fenebrutinib in Rms Patients II · 2024 | Their institution | $3,309 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1548624661
- Licence
- CA A137774California A137774: Current · expires 2027-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-04-06
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.